TY - JOUR
T1 - Impact of contact force technology on atrial fibrillation ablation
T2 - A meta-analysis
AU - Shurrab, Mohammed
AU - Di Biase, Luigi
AU - Briceno Gomez, David F.
AU - Kaoutskaia, Anna
AU - Haj-Yahia, Saleem
AU - Newman, David
AU - Lashevsky, Ilan
AU - Nakagawa, Hiroshi
AU - Crystal, Eugene
N1 - Publisher Copyright:
© 2015 The Authors.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Background-Catheter-tissue contact is essential for effective lesion formation, thus there is growing usage of contact force (CF) technology in atrial fibrillation ablation. We conducted a meta-analysis to assess the impact of CF on clinical outcomes and procedural parameters in comparison to conventional catheter for atrial fibrillation ablation. Methods and Results-An electronic search was performed using major databases. Outcomes of interest were recurrence rate, major complications, total procedure, and fluoroscopic times. Continuous variables were reported as standardized mean difference; odds ratios were reported for dichotomous variables. Eleven studies (2 randomized controlled studies and 9 cohorts) involving 1428 adult patients were identified. CF was deployed in 552 patients. The range of CF used was between 2 to 60 gramforce. The follow-up period ranged between 10 and 53 weeks. In comparing CF and conventional catheter groups, the recurrence rate was lower with CF (35.1% versus 45.5%, odds ratio 0.62 [95% CI 0.45-0.86], P=0.004). Shorter procedure and fluoroscopic times were achieved with CF (procedure time: 156 versus 173 minutes, standardized mean difference -0.85 [95% CI -1.48 to -0.21], P=0.009; fluoroscopic time: 28 versus 36 minutes, standardized mean difference -0.94 [95% CI -1.66; -0.21], P=0.01). Major complication rate was lower numerically in the CF group but not statistically significant (1.3% versus 1.9%, odds ratio 0.71 [95% CI 0.29-1.73], P=0.45). Conclusions-The use of CF technology results in significant reduction of the atrial fibrillation recurrence rate after atrial fibrillation ablation in comparison to the conventional catheter group. CF technology is able to significantly reduce procedure and fluoroscopic times without compromising complication rate.
AB - Background-Catheter-tissue contact is essential for effective lesion formation, thus there is growing usage of contact force (CF) technology in atrial fibrillation ablation. We conducted a meta-analysis to assess the impact of CF on clinical outcomes and procedural parameters in comparison to conventional catheter for atrial fibrillation ablation. Methods and Results-An electronic search was performed using major databases. Outcomes of interest were recurrence rate, major complications, total procedure, and fluoroscopic times. Continuous variables were reported as standardized mean difference; odds ratios were reported for dichotomous variables. Eleven studies (2 randomized controlled studies and 9 cohorts) involving 1428 adult patients were identified. CF was deployed in 552 patients. The range of CF used was between 2 to 60 gramforce. The follow-up period ranged between 10 and 53 weeks. In comparing CF and conventional catheter groups, the recurrence rate was lower with CF (35.1% versus 45.5%, odds ratio 0.62 [95% CI 0.45-0.86], P=0.004). Shorter procedure and fluoroscopic times were achieved with CF (procedure time: 156 versus 173 minutes, standardized mean difference -0.85 [95% CI -1.48 to -0.21], P=0.009; fluoroscopic time: 28 versus 36 minutes, standardized mean difference -0.94 [95% CI -1.66; -0.21], P=0.01). Major complication rate was lower numerically in the CF group but not statistically significant (1.3% versus 1.9%, odds ratio 0.71 [95% CI 0.29-1.73], P=0.45). Conclusions-The use of CF technology results in significant reduction of the atrial fibrillation recurrence rate after atrial fibrillation ablation in comparison to the conventional catheter group. CF technology is able to significantly reduce procedure and fluoroscopic times without compromising complication rate.
KW - Ablation
KW - Atrial fibrillation
KW - Contact force
KW - Meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85006228129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006228129&partnerID=8YFLogxK
U2 - 10.1161/JAHA.115.002476
DO - 10.1161/JAHA.115.002476
M3 - Article
C2 - 26391136
AN - SCOPUS:85006228129
SN - 2047-9980
VL - 4
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 9
M1 - e002476
ER -